Get the Stockscreener App
7.27
9.00%
0.60
After Hours:
7.22
-0.05
-0.69%
Protara Therapeutics Inc stock is traded at $7.27, with a volume of 1.82M.
It is up +9.00% in the last 24 hours and up +30.99% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$6.67
Open:
$6.6
24h Volume:
1.82M
Relative Volume:
2.01
Market Cap:
$389.58M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-2.578
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
+29.82%
1M Performance:
+30.99%
6M Performance:
+118.32%
1Y Performance:
+63.37%
1-Day Range:
$6.55
$7.35
1-Week Range:
$5.5601
$7.35
52-Week Range:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
7.27 | 357.43M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Smart Money: What is the target price for Humacyte Inc Equity Warrant stockRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Aug Sentiment: What is Protara Therapeutics Incs market positionMarket Growth Summary & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛
Protara to present bladder cancer treatment data at ASCO symposium By Investing.com - Investing.com Nigeria
Protara to present bladder cancer treatment data at ASCO symposium - Investing.com
Bladder cancer trial shares new results from 25 patients at ASCO - Stock Titan
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium - Sahm
How strong is Protara Therapeutics Inc. stock revenue growthRate Hike & Accurate Intraday Trading Signals - bollywoodhelpline.com
Earnings Miss: Is Protara Therapeutics Inc being accumulated by smart moneyQuarterly Performance Summary & Trade Opportunity Analysis - baoquankhu1.vn
Is Immatics NV a strong candidate for buy and hold2025 Major Catalysts & Intraday High Probability Setup Alerts - baoquankhu1.vn
CEO Change: What chart patterns are forming on Protara Therapeutics Inc2025 Market WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Earnings Update: What is the cash position of Protara Therapeutics IncJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) down to US$264m market cap, but institutional owners may not be as affected after a year of 5.8% returns - simplywall.st
Weekly Trades: What makes Protara Therapeutics Inc stock attractive todayJuly 2025 Setups & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Published on: 2026-01-14 06:06:18 - Bộ Nội Vụ
Protara, Ceribell rise on FDA breakthrough designations - MSN
Protara to report interim results from BCG-unresponsive trial in Q1 - Investing.com Canada
Protara Therapeutics (TARA) Anticipates Key Milestones by 2026 - GuruFocus
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones - GlobeNewswire
Protara Therapeutics (NASDAQ:TARA) Research Coverage Started at Piper Sandler - Defense World
Protara Therapeutics (NASDAQ:TARA) Upgraded to Strong-Buy at Piper Sandler - MarketBeat
Revenue per share of Protara Therapeutics, Inc. – DUS:1KPA - TradingView — Track All Markets
Why Protara Therapeutics Inc. stock could see breakout soonPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - Улправда
Sectors Review: Why Protara Therapeutics Inc. stock is recommended by analystsMarket Activity Summary & Fast Gaining Stock Strategy Reports - ulpravda.ru
Is Protara Therapeutics Inc. stock overvalued by current metricsMarket Movers & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Protara Therapeutics completes $75 million stock offering - MSN
Can Protara Therapeutics Inc. stock attract ESG capital inflows2025 Volatility Report & Free Expert Approved Momentum Trade Ideas - Улправда
Why Protara Therapeutics Inc. stock is popular among millennialsJuly 2025 Closing Moves & Weekly Market Pulse Updates - ulpravda.ru
Should I hold or sell Protara Therapeutics Inc. stock in 2025Analyst Downgrade & Risk Adjusted Buy and Sell Alerts - Улправда
Is Protara Therapeutics Inc. stock in correction or buying zoneBull Run & Weekly Watchlist for Hot Stocks - ulpravda.ru
Why Protara Therapeutics Inc. stock is recommended by analysts2025 Price Action Summary & Technical Pattern Alert System - Улправда
TD Cowen Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Piper Sandler initiates Protera Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada
Protara begins patient dosing in phase 3 trial for IV choline therapy - Investing.com Nigeria
Protara Therapeutics (TARA) Begins Phase 3 THRIVE-3 Trial for Ke - GuruFocus
TARA Stock Initiated with 'Overweight' Rating by Piper Sandler | - GuruFocus
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support - The Manila Times
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Why analysts recommend Protara Therapeutics Inc. (1KPA) stock2026 world cup usa national team semifinals young talents counter attacking expert forecast statistical analysis - ulpravda.ru
Why Protara Therapeutics Inc. stock could outperform in 20252026 world cup usa national team quarterfinals young talents high defensive line tactical prediction insights - Улправда
Protara gets FDA breakthrough therapy and fast track designations for TARA-002 - MSN
FDA grants breakthrough therapy designation to Protara’s LM treatment By Investing.com - Investing.com Nigeria
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Movement Recap: How strong is Protara Therapeutics Inc stock revenue growthJuly 2025 PostEarnings & Long-Term Capital Growth Strategies - moha.gov.vn
Protara Therapeutics updates on TARA-002 development - The Pharma Letter
Protara, CeriBell rise on FDA breakthrough designations (TARA:NASDAQ) - Seeking Alpha
Protara Therapeutics (TARA) Gains FDA Designations for TARA-002 - GuruFocus
FDA grants breakthrough therapy designation to Protara’s LM treatment - Investing.com
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):